ArticleScientific reports2025
The claudin family characteristics in pan-cancer and the role of claudin12 in the malignant progression of lung adenocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Claudins (CLDNs), pivotal components of tight junctions (TJs), are integral to epithelial barrier function, cell polarity, and paracellular permeability as well as in tumor initiation and development. Among the histological subtypes of lung cancer, lung adenocarcinoma (LUAD) predominates and is frequently diagnosed at an advanced stage, contributing to its dismal 5-year survival rate and posing a significant threat to patient survival. In this work, the expression, prognosis and diagnostic of CLDNs in pan-cancer were analyzed using bioinformatics. In particular, the relationship between claudin12 (CLDN12) and the expression, prognosis and clinical stage in LUAD was paid attention to, and the diagnostic efficiency of CLDN12 was evaluated by receiver operator characteristic curve. The PPI network was constructed using STRING database, followed by Cytoscape-assisted hub gene identification. Functional enrichment analyses (GO and KEGG) were conducted to elucidate potential signaling pathways linked to CLDN12. These results showed that CLDNs were differentially expressed in pan-cancer, and were valuable for the prognosis and diagnosis of tumors. Specifically, CLDN12 was significantly upregulated in LUAD, correlating with advanced tumor stage, lymph nodes metastasis, and poor survival outcomes. In vitro functional assays revealed that CLDN12 knockdown suppressed LUAD cell proliferation, migration, and invasion while promoting cell apoptosis. In summary, CLDN12 may serve as a promising biomarker for LUAD detection and a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.